Medicamen Biotech Ltd

Medicamen Biotech Ltd

₹ 425 0.84%
11 Jun - close price
About

Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations[1]

Key Points

Business Overview:[1][2][3]
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.

  • Market Cap 576 Cr.
  • Current Price 425
  • High / Low 630 / 375
  • Stock P/E 60.9
  • Book Value 171
  • Dividend Yield 0.24 %
  • ROCE 6.55 %
  • ROE 4.44 %
  • Face Value 10.0

Pros

Cons

  • Promoter holding has decreased over last quarter: -2.53%
  • The company has delivered a poor sales growth of 5.24% over past five years.
  • Company has a low return on equity of 6.45% over last 3 years.
  • Earnings include an other income of Rs.6.23 Cr.
  • Dividend payout has been low at 10.5% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
22.75 33.09 33.53 34.12 37.15 40.50 42.67 44.20 45.01 41.48 42.84 41.14 26.00
17.78 27.43 27.67 28.26 30.38 33.09 36.51 38.61 38.18 36.62 36.29 34.90 27.10
Operating Profit 4.97 5.66 5.86 5.86 6.77 7.41 6.16 5.59 6.83 4.86 6.55 6.24 -1.10
OPM % 21.85% 17.10% 17.48% 17.17% 18.22% 18.30% 14.44% 12.65% 15.17% 11.72% 15.29% 15.17% -4.23%
0.34 0.96 0.52 0.63 0.35 0.38 0.55 0.83 0.54 0.58 0.29 0.14 5.22
Interest 0.56 0.77 0.62 0.68 0.86 0.96 0.91 0.65 1.87 0.68 1.01 0.73 0.62
Depreciation 1.52 1.53 1.62 1.60 1.61 1.68 1.80 1.76 1.77 1.74 2.57 2.17 0.47
Profit before tax 3.23 4.32 4.14 4.21 4.65 5.15 4.00 4.01 3.73 3.02 3.26 3.48 3.03
Tax % 14.55% 17.13% 13.04% 10.69% 13.12% 14.37% 24.75% 31.17% 16.62% 25.17% 30.06% 27.59% 20.79%
2.75 3.59 3.61 3.76 4.05 4.42 3.01 2.77 3.10 2.26 2.27 2.52 2.41
EPS in Rs 2.25 2.94 2.85 2.97 3.20 3.49 2.38 2.19 2.44 1.78 1.79 1.98 1.90
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
73 78 67 82 112 123 117 110 115 138 172 151
68 73 62 71 95 105 99 90 91 113 145 135
Operating Profit 5 5 6 12 17 17 18 20 24 25 27 17
OPM % 7% 6% 8% 14% 15% 14% 15% 18% 21% 18% 16% 11%
1 1 1 0 2 4 2 1 2 2 2 6
Interest 4 4 4 4 3 1 1 2 2 3 6 3
Depreciation 2 2 2 2 2 2 2 3 6 6 7 7
Profit before tax 0 0 1 6 14 18 17 17 18 17 17 13
Tax % 44% -267% 32% 19% 27% 31% 26% 25% 18% 13% 21% 26%
0 0 0 5 10 12 12 12 15 15 13 9
EPS in Rs 0.10 0.46 0.48 4.91 8.89 10.28 10.04 10.22 12.20 11.86 10.46 7.44
Dividend Payout % 0% 0% 0% 0% 12% 10% 5% 10% 8% 8% 10% 13%
Compounded Sales Growth
10 Years: 7%
5 Years: 5%
3 Years: 9%
TTM: -12%
Compounded Profit Growth
10 Years: 36%
5 Years: -5%
3 Years: -14%
TTM: -29%
Stock Price CAGR
10 Years: 38%
5 Years: 7%
3 Years: -13%
1 Year: -12%
Return on Equity
10 Years: 9%
5 Years: 8%
3 Years: 6%
Last Year: 4%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 9 10 10 11 12 12 12 12 12 13 13 13
Reserves 8 8 8 16 63 75 110 122 136 181 196 205
15 21 19 18 14 12 11 19 26 26 30 27
33 31 23 29 28 38 43 39 52 57 55 48
Total Liabilities 65 69 60 73 118 137 176 192 226 277 294 293
22 20 19 19 25 24 34 90 92 92 91 86
CWIP 1 0 0 0 0 15 40 0 0 0 0 0
Investments 0 0 0 0 0 0 2 2 2 4 8 8
42 49 41 54 92 97 100 101 131 180 195 199
Total Assets 65 69 60 73 118 137 176 192 226 277 294 293

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
5 -3 6 4 -5 4 12 13 5 -4 -0 -2
-1 0 -1 -2 -8 -15 -39 -18 -8 -8 -9 -2
-4 3 -5 -1 33 -4 21 6 4 28 3 -7
Net Cash Flow 1 -0 0 0 20 -14 -6 1 1 17 -6 -11

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 102 124 87 114 126 129 137 165 193 159 102 141
Inventory Days 95 95 95 102 77 67 85 28 188 230 237 274
Days Payable 209 187 160 165 118 134 160 161 291 232 152 182
Cash Conversion Cycle -13 32 22 51 85 62 62 32 91 157 188 234
Working Capital Days 44 80 83 96 135 151 162 166 207 213 178 250
ROCE % 13% 12% 12% 24% 25% 20% 15% 13% 12% 11% 10% 7%

Shareholding Pattern

Numbers in percentages

1 Recently
Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Apr 2025
43.21% 43.21% 43.21% 43.21% 43.21% 43.21% 43.21% 42.99% 42.99% 42.99% 43.16% 40.46%
1.83% 0.17% 0.19% 0.16% 0.22% 0.22% 0.12% 0.06% 0.06% 0.06% 0.12% 0.22%
0.13% 0.20% 0.20% 0.20% 0.20% 0.67% 0.99% 1.17% 1.17% 0.87% 0.69% 0.65%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.06% 0.06% 0.05%
54.84% 56.42% 56.40% 56.44% 56.38% 55.90% 55.69% 55.78% 55.79% 56.04% 55.99% 58.62%
No. of Shareholders 8,3328,2738,2338,2729,41910,25210,63910,65210,79210,57610,43510,592

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls